Lilly's diabetes drug trumps Sanofi's in late-stage trials

Sept 4 (Reuters) - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.